Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-08-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于向控股股东进行永续债权融资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding a perpetual debt financing transaction with its controlling shareholder, Lhasa Ailike Investment Consulting Co., Ltd. The text details the terms of the financing, the relationship between the parties, pricing policies, approval procedures, and opinions from intermediaries. It is a formal disclosure about a financing transaction and related party transaction, including board and shareholder approvals. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a presentation, call transcript, or legal proceeding update. It is a capital/financing update about a specific financing transaction involving perpetual debt and related party dealings. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is about 4,836 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-08-21 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司向控股股东进行永续债权融资暨关联交易事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities Co., Ltd. regarding a perpetual debt financing transaction between Beijing Shenzhou Cell Biotechnology Group Co., Ltd. and its controlling shareholder. It includes descriptions of the transaction, related party relationships, pricing policies, contract terms, necessity and impact of the transaction, and the approval process by the board, audit committee, and supervisory board. The document is not a financial report, earnings release, or regulatory filing per se, but rather a formal verification and opinion on a related-party transaction and financing matter. This type of document aligns with an Audit Report / Information (AR) category, as it involves an independent sponsor's review and opinion on a specific financial transaction and compliance with regulatory rules, without being a full annual or interim report. The document length (4831 characters) and content support this classification rather than a simple announcement or regulatory filing. FY 2024
2024-08-21 Chinese
神州细胞关于公司监事辞任及补选监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor and the nomination of a replacement supervisor. It details the circumstances of the resignation, the legal compliance, and the qualifications of the proposed new supervisor. There is no financial data, no discussion of financial results, no mention of annual or interim reports, and no indication of shareholder voting results. The content focuses on changes in the company's supervisory board members, which fits the category of Board/Management Information (MANG). The document length is short and it is a formal announcement of personnel changes rather than a report or presentation.
2024-08-21 Chinese
神州细胞2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年半年度报告' which translates to '2024 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company business overview, product pipeline, and other comprehensive information typical of a half-year financial report. The report period is specified as January 1, 2024 to June 30, 2024, confirming it is an interim period report. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-21 Chinese
神州细胞关于参加2023年度制药专场集体业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in a 2023 annual pharmaceutical sector collective performance explanation meeting. It mentions the meeting will be held via video recording and online interaction, focusing on the 2023 annual and 2024 first quarter operating results and financial indicators. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the upcoming investor presentation event and how to participate. The document length is short (1421 characters), and it serves as a notice for an investor presentation rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, or possibly a Report Publication Announcement (RPA). However, since it is about an investor meeting and explanation session, the best fit is Investor Presentation (IP).
2024-05-10 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2023年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2023年度持续督导跟踪报告" (2023 Annual Continuous Supervision Follow-up Report) issued by CITIC Securities as the sponsor for Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It references regulatory frameworks such as the Shanghai Stock Exchange STAR Market listing rules and details extensive supervisory activities including review of governance, financials, internal controls, fundraising usage, and risk factors. The document contains detailed financial data for 2023, risk disclosures, and operational updates. It is a comprehensive supervisory report issued by the sponsor to fulfill continuous supervision obligations post-IPO or issuance. This type of document is not a full annual report (10-K), nor an audit report, nor a simple announcement. It is a continuous supervision report typically classified under Regulatory Filings (RNS) as it is a regulatory compliance document reporting ongoing supervision and findings rather than a formal financial report or earnings release. The length (15,000 characters) and detailed content confirm it is not a brief announcement or certification. Therefore, the best fitting category is Regulatory Filings (RNS).
2024-05-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.